<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463681</url>
  </required_header>
  <id_info>
    <org_study_id>2018-000582-36</org_study_id>
    <nct_id>NCT03463681</nct_id>
  </id_info>
  <brief_title>A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma</brief_title>
  <acronym>BREAKPOINT</acronym>
  <official_title>A Phase 2 Open Label Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma Pretreated With One immunochecKPOint INhibiTor (Anti PD1/PDL1): the BREAKPOINT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label single arm, multicenter, phase II study designet To assess the&#xD;
      progression free survival (PFS) of cabozantinib in patients pretreated with one&#xD;
      immunocheckpoint inhibitor (CPI) in monotherapy or in combination&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 11, 2018</start_date>
  <completion_date type="Actual">April 8, 2021</completion_date>
  <primary_completion_date type="Actual">April 8, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>28 month</time_frame>
    <description>To assess the progression free survival (PFS) of cabozantinib in patients pretreated with one immunocheckpoint inhibitor (CPI) in monotherapy or in combination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>28 month</time_frame>
    <description>To assess the overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rates (ORR)</measure>
    <time_frame>28 month</time_frame>
    <description>the efficacy based on objective response rates (ORR) according to RECIST 1:1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>28 month</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cabozantinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all subjects will recieve open label Cabozantinib 60 mg orally once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabometyx</intervention_name>
    <description>cabozantinib 60 mg orally once daily</description>
    <arm_group_label>Cabozantinib</arm_group_label>
    <other_name>cabozantinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent&#xD;
&#xD;
          2. One previous anticancer treatment with a PD1/PDL1 inhibitor, as monotherapy or in&#xD;
             combination with an angiogenesis inhibitor or anti CTLA 4, in both setting first line&#xD;
             or adjuvant ( in this case patient having recurrence during the adjuvant treatment or&#xD;
             within 6 months after therapy with PD1-PD-L1 therapy)&#xD;
&#xD;
          3. Age ≥18 years&#xD;
&#xD;
          4. Patients with histological diagnosis of predominant clear cells renal cell carcinoma&#xD;
&#xD;
          5. Measurable disease (as per RECIST 1.1 criteria) with documented radiological&#xD;
             progression&#xD;
&#xD;
          6. Fertile women (&lt;2 years after last menstruation) and men of childbearing potential&#xD;
             must use effective methods of contraception (oral contraceptives, intrauterine&#xD;
             contraceptive device, barrier method of contraception in conjunction with spermicidal&#xD;
             jelly or surgical sterilisation) during the study and for 4 months after the last dose&#xD;
             of study treatment&#xD;
&#xD;
          7. All sites of disease including brain metastases (non symptomatic)&#xD;
&#xD;
          8. Karnofsky performance status ≥ 70%&#xD;
&#xD;
          9. Life expectancy greater than 3 months&#xD;
&#xD;
         10. The required values at baseline are as follows:&#xD;
&#xD;
               -  Absolute neutrophil count &gt;1.5 x 109 /L,&#xD;
&#xD;
               -  Platelet count &gt; 100 x 109 /L,&#xD;
&#xD;
               -  Haemoglobin &gt; 9g/dl,&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 upper limit of normal (ULN);&#xD;
&#xD;
               -  AST, ALT&lt;2.5 ULN in patients without liver metastases, &lt;5 ULN in patients with&#xD;
                  liver metastases;&#xD;
&#xD;
               -  serum creatinine &lt; 2.0 mg/dl, amylase and lipase &lt;1.5 ULN 11- Female subjects of&#xD;
                  childbearing potential must not be pregnant at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Major surgical procedure within 28 days prior to study treatment start&#xD;
&#xD;
          2. Other malignancies within the last 5 years (other than curatively treated basal cell&#xD;
             carcinoma of the skin and/or in situ carcinoma of the cervix, meningiomas)&#xD;
&#xD;
          3. Clinically significant cardiovascular disease, for example cerebrovascular accidents&#xD;
             (&lt;6 months), myocardial infarction (&lt;6 months), unstable angina, New York Heart&#xD;
             Association (NYHA) grade II or greater congestive heart failure or serious cardiac&#xD;
             arrhythmia requiring medication&#xD;
&#xD;
          4. Recent (within the 30 days prior to randomisation) treatment with another&#xD;
             investigational drug or participation in another investigational study&#xD;
&#xD;
          5. Symptomatic brain metastasis&#xD;
&#xD;
          6. History of other disease, metabolic dysfunction, physical examination finding or&#xD;
             clinical laboratory finding giving reasonable suspicion of a disease condition that&#xD;
             contraindicates use of an investigational drug or patient at high risk from treatment&#xD;
             complications&#xD;
&#xD;
          7. PT or INR and PTT &gt;1.5 times the Upper Normal Limit of the institution (patient who&#xD;
             are being therapeutically anticoagulated with an agent such as warfarin or heparin&#xD;
             will be allowed to participate provided that no prior evidence of underlying&#xD;
             abnormality in these parameters exists).For patients on warfarin, close monitoring of&#xD;
             at least weekly evaluations will be performed, until INR is stable based on a&#xD;
             measurement at pre-dose, as defined by the local standard of care&#xD;
&#xD;
          8. Previous or concomitant radiotherapy in the lesion parameter of disease&#xD;
&#xD;
          9. Previous radiotherapy or other locoregional antitumoral treatment performed within 21&#xD;
             days before the study recruitment&#xD;
&#xD;
         10. Uncontrolled hypertension (&gt;= 160 mmHg systolic and/or 90 mmHg diastolic) while&#xD;
             receiving chronic medication&#xD;
&#xD;
         11. Inability to swallow tablets or capsules&#xD;
&#xD;
         12. Female subject who is pregnant or breast-feeding. Confirmation that the subject is not&#xD;
             pregnant must be established by a negative serum β-human chorionic gonadotropin&#xD;
             (β-hCG) pregnancy test result obtained during screening. Pregnancy testing is not&#xD;
             required for post-menopausal or surgically sterilized women&#xD;
&#xD;
         13. Known history of human immunodeficiency virus (HIV) infection, active hepatitis B, or&#xD;
             active hepatitis C.&#xD;
&#xD;
         14. Rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or&#xD;
             glucose-galactose malabsorption&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Procopio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS ISTITUTO NAZIONALE TUMORI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Derosa L, Rouche JA, Colomba E et al. Efficacy of cabozantinib after PD1/PDL1 checkpoint inhibitors in metastatic renal cell carcinoma (mRCC): the gustave Roussy experience. Ann of Onc vol 28, sep 2017</citation>
  </reference>
  <reference>
    <citation>Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer. 2019 Jun;114:67-75. doi: 10.1016/j.ejca.2019.04.003. Epub 2019 May 7.</citation>
    <PMID>31075726</PMID>
  </reference>
  <reference>
    <citation>Ref: Brookmeyer, R and Crowley, JJ (1982): A confidence interval for the median survival time. Biometrics 38:29-41</citation>
  </reference>
  <results_reference>
    <citation>Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25.</citation>
    <PMID>26406150</PMID>
  </results_reference>
  <results_reference>
    <citation>Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ; METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5.</citation>
    <PMID>27279544</PMID>
  </results_reference>
  <results_reference>
    <citation>Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017 Feb 20;35(6):591-597. doi: 10.1200/JCO.2016.70.7398. Epub 2016 Nov 14. Erratum in: J Clin Oncol. 2017 Nov 10;35(32):3736. J Clin Oncol. 2018 Feb 10;36(5):521.</citation>
    <PMID>28199818</PMID>
  </results_reference>
  <results_reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </results_reference>
  <results_reference>
    <citation>Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC, Mainwaring PN, Hammers HJ, Lee JL, Roth BJ, Marteau F, Williams P, Baer J, Mangeshkar M, Scheffold C, Hutson TE, Pal S, Motzer RJ, Choueiri TK. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. J Clin Oncol. 2018 Mar 10;36(8):757-764. doi: 10.1200/JCO.2017.75.2170. Epub 2018 Jan 29.</citation>
    <PMID>29377755</PMID>
  </results_reference>
  <results_reference>
    <citation>Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989.</citation>
    <PMID>23964934</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

